Johnson & Johnson(JNJ)

NEW BRUNSWICK, NJPharmaceutical1 H-1B visas (FY2023)

Focus: Johnson & Johnson is a diversified Big Pharma giant with $85.2B in FY2025 revenue, operating across pharmaceuticals, medical devices, and consumer health with 131,900 employees globally. Market leader in cardiovascular, oncology, immunology, and infectious disease segments.

Oncology Immunology Neuroscience Cardiovascular

Profile data last refreshed 16h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Employees

131,900

Open Jobs

About Johnson & Johnson

AI assessmentNot Hiring

No open roles listed right now. Follow Johnson & Johnson to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

6/9 — Partial

Company HealthSolid

Pipeline

Early-stage

50 total

LOE Risk

5 imminent

EDURANT

Hiring

Stable

Revenue

$85.2B

FY2025

Key Products

XARELTO

Atrial Fibrillation, Venous Thromboembolism, Pulmonary Embolism

$6.3B

Peak

Represents 48% of company revenue and drives profitability; FXa inhibitor in stable cardiovascular market with no disclosed LOE date.

Help build intelligence for Johnson & Johnson

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Massive scale (131,900 employees) and diversification provide job security and internal mobility across therapeutic areas and geographies
Blockbuster portfolio with XARELTO ($6.3B Part D spending) and INVEGA SUSTENNA ($1.8B) generating stable cash for R&D investment
Active hiring across 1,034 open roles with strongest demand in Commercial (319 roles), Engineering (159), and Clinical Operations (156)

Watch Out For

Critically low R&D intensity (1%) signals limited investment in early-stage innovation relative to revenue, constraining pipeline depth and career growth in research-heavy roles
Imminent patent cliff on $3.2B in revenue (INVOKANA, OPSUMIT, INVEGA SUSTENNA) by 2031 creates restructuring risk and job security uncertainty in commercial and manufacturing functions
Weak H1B sponsorship (only 1 approval in 2023) severely limits visa pathways for international candidates

Generated by Claude from Johnson & Johnson's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

INVEGA SUSTENNA

Schizophrenia, Schizoaffective Disorder

$1.8B

Peak4.7yr

Second-largest revenue contributor faces patent cliff in 2031; long-acting antipsychotic with strong market position but limited patent runway.

ERLEADA

Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer

$1.1B

Peak13.7yr

Androgen receptor inhibitor with extended patent protection until 2040; litigation ongoing with Bayer over claims but market position remains strong.

OPSUMIT

Pulmonary Arterial Hypertension

$1.0B

Peak3.5yr

Endothelin receptor antagonist facing patent cliff in 2029; critical revenue at risk within 3 years as LOE approaches.

UPTRAVI

Pulmonary Hypertension

$758M

Peak11.1yr

Prostacyclin receptor agonist with longer patent runway until 2037; smaller but stable revenue contributor in rare disease segment.

Pipeline & Clinical Trials

TEST LENS

Ocular Physiology

N/A

Clinical Trials (1)

NCT05502289Clinical Evaluation of Delefilcon A and Verofilcon A Daily Disposable Toric Soft Contact Lenses Over One Week of Wear

N/A

Test 8.5BC

Visual Acuity

N/A

Clinical Trials (1)

NCT03139578Short-Term Clinical Comparison of Two Silicone Hydrogel Daily Disposable Contact Lenses

N/A

etafilcon A control lens

Refractive Ametropia

N/A

Clinical Trials (1)

NCT01484028Evaluation of the Performance of Two Contact Lenses Compared to a Marketed Lens

N/A

Allergy and Asthma Following Children Who Were Fed Supplemented Infant Formula

Allergy

N/A

Clinical Trials (1)

NCT00740974Allergy and Asthma Following Children Who Were Fed Supplemented Infant Formula

N/A

Bioequivalence Study of Patches With Different Release Profiles

Female Contraception

N/A

Clinical Trials (1)

NCT00697307Bioequivalence Study of Patches With Different Release Profiles

N/A

Wash IP

Dermatitis, Atopic

N/A

Clinical Trials (1)

NCT04740892A Study of a Moisturizing Cream and Baby Wash in the Management of Mild to Moderate Atopic Dermatitis in Infants, Toddlers and Children

N/A

senofilcon A contact lenses

Ametropia

N/A

Clinical Trials (1)

NCT03319212Clinical Characterization of Symptomatic Populations

N/A

ACUVUE OASYS 1-Day for Astigmatism

Visual Acuity

N/A

Clinical Trials (1)

NCT06649019Evaluation of Lens Rotation in Habitual Wearers of Toric, Soft Contact Lenses

N/A

Toric Multifocal etafilcon A with PVP

Visual Acuity

N/A

Clinical Trials (1)

NCT03713281Evaluation of a Toric Multifocal Contact Lens Manufactured in Etafilcon Material in a Low ADD Hyperopic Population

N/A

SPF50+

Sun Protection

N/A

Clinical Trials (1)

NCT02952235Evaluation of Sunscreens Under Actual Use Conditions

N/A

Sunscreen A

Sunscreen

N/A

Clinical Trials (1)

NCT05565625A Study to Evaluate the Whitening Effect of Mineral Sunscreens in Multi-Cultural Skin Tones

N/A

Model C0002

Cataracts

N/A

Clinical Trials (1)

NCT05531292PROOF-OF-CONCEPT STUDY FOR NEW INTRAOCULAR LENS, MODEL C0002

N/A

Dyad training

Technical Skills Training

N/A

Clinical Trials (1)

NCT02895685Group Dynamics in Surgical Skill Training

N/A

JJVC Investigational Multifocal Contact Lens

Visual Acuity

N/A

Clinical Trials (1)

NCT04615507Evaluation of a Daily Disposable Novel Multifocal Contact Lens in a Myopic Population; Part 2

N/A

etafilcon A

Visual Acuity

N/A

Clinical Trials (1)

NCT03059810Clinical Evaluation of Investigational Multifocal Contact Lenses

N/A

alphafilcon A toric

Ametropia

N/A

Clinical Trials (1)

NCT00630305Endothelial Bleb Response With Toric Lenses

N/A

Amino Acid formula

Cow's Milk Allergy

N/A

Clinical Trials (1)

NCT01584245Evaluation of the Efficacy of an Amino Acid Based Formula in Infants

N/A

JJVC Investigational Contact Lens

Visual Acuity

N/A

Clinical Trials (1)

NCT04287036Objective Vision Evaluation of Two Cosmetic Contact Lenses

N/A

Experimental - Tampon with GML

Vaginal Microflora

N/A

Clinical Trials (1)

NCT00913523Clinical Evaluation of Effects of an Investigational Tampon on Vaginal Microflora

N/A

Marketed Contact Lens

Tear Film Characteristics

N/A

Clinical Trials (1)

NCT02760810Clinical Evaluation of An Approved Contact Lens

N/A

Feeback group

Adult Smokers

N/A

Clinical Trials (1)

NCT00529256Evaluation of Organisational Changes to Promote Smoking Cessation

N/A

Professional medical interpreter

Language Discordance

N/A

Clinical Trials (1)

NCT01041014Cost Effectiveness of Language Services in Hospital Emergency Departments (EDs)

N/A

Formula PD-F-7716

Inadequate Lubrication

N/A

Clinical Trials (1)

NCT01271036Safety Study of a Sensitive Sensual Touch and Personal Lubricant

N/A

Vertebroplasty

Vertebral Compression Fractures

N/A

Clinical Trials (1)

NCT06670404Prospective Evaluation of Therapeutic Combination in Treating Vertebral Compression Fractures

N/A

INFUSE® One Day Multifocal

Visual Acuity

N/A

Clinical Trials (1)

NCT07076160Pilot Dispensing Study of Two Marketed Daily Disposable Multifocal Contact Lenses

N/A

TRP-200

Visual Acuity

N/A

Clinical Trials (1)

NCT04885296Evaluation of Prototype Lenses With Experimental UV/HEV Blocker

N/A

Cheetah System

Myopia

N/A

Clinical Trials (1)

NCT04200898Clinical Investigation of the Cheetah System For The Correction of Myopia With and Without Astigmatism

N/A

Colgate® Regular Cavity Protection

Tooth Stain

N/A

Clinical Trials (1)

NCT02151058A Clinical Trial to Test the Effect of a Marketed Mouth Rinse on Stain Removal

N/A

bi-planer radiography

Femoro Acetabular Impingement

N/A

Clinical Trials (1)

NCT04418596Longitudinal Follow-up of Male Soccer Players Prone to Developing CAM Hip Deformity

N/A

etafilcon A

Visual Acuity

N/A

Clinical Trials (1)

NCT02679976Marketed Contact Lens Real World Through Focus Curve

N/A

Education

Food Insecurity

N/A

Clinical Trials (1)

NCT02558660Evaluating Use of a Farmers Market Incentive Program Among Low-Income Health Center Patients

N/A

JJVC Investigational Multifocal Contact Lens

Visual Acuity

N/A

Clinical Trials (1)

NCT04310566Evaluation of a Daily Disposable Novel Multifocal Contact Lens in a Myopic Population

N/A

Infant formula

Healthy Term Infants

N/A

Clinical Trials (1)

NCT00712608The Evaluation of Cow's Milk Formula - Study B

N/A

Motivational Interviewing to Address Suicidal Ideation- Revised

Suicide, Attempted

N/A

Clinical Trials (1)

NCT05256940Motivational Interviewing to Address Suicidal Ideation for Veterans at High Risk for Suicide

N/A

ELITA System

Refractive Error

N/A

Clinical Trials (1)

NCT05713253A PHASED, PROSPECTIVE, MULTI-CENTER STUDY OF THE ELITA SYSTEM

N/A

JJVC Investigational Multifocal Contact Lens

Visual Acuity

N/A

Clinical Trials (1)

NCT04794751Evaluation of Investigational Daily Disposable Multifocal Contact Lenses Produced With Different Manufacturing Processes

N/A

Nutritional Beverage

Concentration

N/A

Clinical Trials (1)

NCT01355601Effect of Carbohydrates From Nutritional Beverages in Children

N/A

Tecnis Symfony Optiblue/Tecnis Symfony Optiblue Toric

Cataract

N/A

Clinical Trials (1)

NCT06567834Clinical Evaluation and Comparison of the Tecnis Symfony Optiblue and Tecnis Symfony IOLs

N/A

Vistakon Investigational Multi-Purpose Solution II

Contact Lens Wear

N/A

Clinical Trials (1)

NCT01055457Vistakon Investigational Multi-purpose Contact Lens Care Solution.

N/A

senofilcon A

Myopia

N/A

Clinical Trials (1)

NCT00975585Clinical Performance Comparison of Two Contact Lenses

N/A

Fall Prevention Tool Kit prototype using a randomized design

Patient Falls

N/A

Clinical Trials (1)

NCT00675935Falls - Tailoring Interventions for Patient Safety

N/A

Characterization of the Edge of Soft Contact Lens and Its Interaction With Ocular Surface

Healthy

N/A

Clinical Trials (1)

NCT00707291Characterization of the Edge of Soft Contact Lens and Its Interaction With Ocular Surface

N/A

Mouth Rinse 19668-012

Gingivitis

N/A

Clinical Trials (1)

NCT01821261A Clinical Trial to Test the Effect of an Experimental Mouth Rinse on Gum Disease

N/A

Group and 1:1 occupational therapy sessions

Occupational Deprivation

N/A

Clinical Trials (1)

NCT07035210Impact of Self-directed Goals for Long-term Patients in a Forensic Hospital: A Mixed-Methods Pilot Study

N/A

JJVC Marketed Contact Lens

Visual Acuity

N/A

Clinical Trials (1)

NCT03431441Clinical Evaluation of 2-Week Reusable ACUVUE 2 Vivid Style

N/A

senofilcon A

Meibomian Gland Dysfunction

N/A

Clinical Trials (1)

NCT01819194Contact Lens Comfort Relative to Meibomian Gland Status

N/A

TEST Contact Lens

Visual Acuity

N/A

Clinical Trials (1)

NCT02756078Clinical Performance Evaluation of Two Silicone Hydrogel Lenses

N/A

Cartoon video describing study information notice

Information Disclosure

N/A

Clinical Trials (1)

NCT05341791Paper Versus Cartoon Video-based Administration of Study Information Notice for Participant Consent

N/A

Follow-up Study After Bankart Repair Using MG-1

Shoulder Dislocation

N/A

Clinical Trials (1)

NCT02228226Follow-up Study After Bankart Repair Using MG-1

N/A

Long-term Caloric Restriction and Cellular Aging Markers

Aging

N/A

Clinical Trials (1)

NCT01256840Long-term Caloric Restriction and Cellular Aging Markers

N/A

Open Jobs (0)

No open positions listed yet.

Interview Prep Quick Facts

Portfolio: 373 approved products, 150 clinical trials

Top TAs: Oncology, Neurology, Infectious Diseases

H-1B (2023): 1 approval

Publications: 50 in PubMed

SEC Filings: 2 available

Portfolio Health

Pre-Launch35 (9%)

Launch7 (2%)

Growth6 (2%)

Peak29 (8%)

LOE Approaching134 (36%)

Post-LOE162

Therapeutic Area Focus

Oncology

40 marketed674 pipeline

Neurology

55 marketed460 pipeline

Infectious Diseases

83 marketed192 pipeline

Immunology

27 marketed203 pipeline

Financials (FY2025)

Revenue

$85.2B6%

R&D Spend

$483M(1%)

Net Income

$35.2B

Cash

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Risk Signals

WARN Act Layoff Notices (2)

2024-09-01

231 employees affected— New Brunswick, NJ

source

2024-09-01

231 employees affected— New Brunswick, NJ

source

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Utility of ACR TI-RADS to determine need for repeat FNA in thyroid nodules with nondiagnostic cytology.

Cancer cytopathology

2026

PMID:41958111

Association of Seasonal Hyperacute Panuveitis Syndrome with S. pneumoniae Endophthalmitis.

chlorhexidine gluconate

CLINICAL PHARMACOLOGY PerioGard® (Chlorhexidine Gluconate Oral Rinse USP, 0.12%) provides antimicrobial activity during oral rinsing. The clinical significance of chlorhexidine gluconate oral rinse's antimicrobial activities is not clear. Microbiological sampling of plaque has shown a general reduction of counts of certain assayed bacteria, both aerobic and anaerobic, ranging from 54-97% through six months' use. Use of chlorhexidine gluconate oral rinse USP, 0.12% in a six-month clinical study did not result in any significant changes in bacterial resistance, overgrowth of potentially opportunistic organisms or other adverse changes in the oral microbial ecosystem. Three months after chlorhexidine gluconate oral rinse USP, 0.12% use was discontinued, the number of bacteria in plaque had returned to baseline levels and resistance of plaque bacteria to chlorhexidine gluconate was equal to that at baseline. PHARMACOKINETICS Pharmacokinetic studies with a chlorhexidine gluconate oral rinse USP, 0.12% indicate approximately 30% of the active ingredient is retained in the oral cavity following rinsing. This retained drug is slowly released into the oral fluids. Studies conducted on human subjects and animals demonstrate chlorhexidine gluconate is poorly absorbed from the gastrointestinal tract. The mean plasma level of chlorhexidine gluconate reached a peak of 0.206 µg/g in humans 30 minutes after they ingested a 300-mg dose of the drug. Detectable levels of chlorhexidine gluconate were not present in the plasma of these subjects 12 hours after the compound was administered. Excretion of chlorhexidine gluconate occurred primarily through the feces (~90%). Less than 1% of the chlorhexidine gluconate ingested by these subjects was excreted in the urine.

17 marketed135 pipeline

Cardiovascular

24 marketed81 pipeline

Ophthalmology

101 pipeline

Respiratory

24 marketed69 pipeline

Source: state DOL filings, aggregated via Big Local News

No recent FDA warnings, WARN Act filings, or public layoffs detected, but patent cliff exposure and low R&D intensity suggest structural headcount risk within 3 years.

Ophthalmology science

Showing 5 of 10 publications

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Johnson & Johnson(JNJ)

About Johnson & Johnson

Why Work Here

Key Products

Watch Out For

Products & Portfolio (53)

Key Products by Revenue

Other Products (24)

Pipeline & Clinical Trials

Recent News · Johnson & Johnson(10)

Open Jobs (0)

Financials (FY2025)

Hiring Trend

Visa Sponsorship

Risk Signals

WARN Act Layoff Notices (2)

Research Publications(10)